Skip to main content
. 2015 Jun 16;126(4):508–519. doi: 10.1182/blood-2014-11-611194

Table 1.

MF tumor samples subjected to WGS

Patient Ethnicity Sex Age, y Tumor site Normal tissue site Pathology Past therapy Current therapy TNMB Clinical stage
1 White Female 70 Knee Back Nontransformed XRT Bexarotene, vorinostat T3, N0, M0, B0 IIB
2 White Male 67 Upper arm Abdomen Granulomatous NB-UVB Bexarotene T3, N2, M0, B0 IIB
3 White Male 41 Forearm Abdomen Nontransformed Bexarotene NB-UVB, topical bexarotene T3, N0, M0, B0 IIB
4 Black Male 35 Scalp Forearm Large cell transformed XRT, ECP bexarotene, romidepsin Gemcitabine T3, N2, M0, B2 IVA1
5 White Female 69 Upper arm Abdomen Nontransformed None None T3, N0, M0, B0 IIB

ECP, extracorporeal photopheresis; NB-UVB, narrow-band UV B; TNMB, tumor, node, metastasis, blood; XRT, local radiation therapy.